Immune protection conferred by recombinant MRLC (myosin regulatory light chain) antigen in TiterMax Gold® adjuvant against experimental fasciolosis in rats.

Vaccine(2017)

Cited 5|Views8
No score
Abstract
•Fasciola hepatica in an important animal and human pathogen.•First experimental trial evaluating Fasciola hepatica MRLC antigen in a rodent model.•51.0% immune protection conferred.
More
Translated text
Key words
MRLC,Fasciola hepatica,Vaccine
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined